• Medicine
  • Published 2017

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

@inproceedings{Wolchok2017SafetyAC,
  title={Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).},
  author={Jedd D. Wolchok and Harriet M. Kluger and Margaret K. Callahan and Michael A Postow and Ruth Ann Gordon and Neil Howard Segal and Naiyer A. Rizvi and Alexander M Lesokhin and Kathleen Reed and Matthew M. Burke and Anne Caldwell and Stephanie Anne Kronenberg and Blessing Agunwamba and William Feely and Quan Hong and Christine E. Horak and Alan J Korman and Jon M. Wigginton and Ashok Kumar Gupta and Mario Sznol},
  year={2017}
}
9012^ Background: CTLA-4 and PD-1 are critical immune checkpoint receptors. In MEL pts, ipilimumab (anti-CTLA-4) prolonged survival in two phase III trials, and nivolumab (anti-PD-1) produced an objective response rate (ORR) of 31% (n=106) in a phase I trial. PD-1 is induced by CTLA-4 blockade, and combined blockade of CTLA-4/PD-1 showed enhanced antitumor activity in murine models. Thus, we initiated the first phase 1 study to evaluate nivolumab/ipilimumab combination therapy. Methods: MEL pts… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS